Quick Links

Thierry Alcindor

Personal Information
Firstname: 
Thierry
Lastname: 
Alcindor
Profile Picture: 
Primary Position
Faculty: 
Faculty of Medicine
Department: 
Oncology
Institute: 
McGill University Health Centre (MUHC)
Position/Appointment: 
Associate Professor
Research Interests: 
Investigator-initiated trials for experimental treatment of various malignancies (GI cancers, sarcoma, lymphoma). Collaboration with cooperative groups and participation to industry-sponsored trials.clinical trials, GI cancers, sarcoma, lymphoma.
Selected Publications: 

Garg A, Nahal A, Tabah R, Turcotte R, Alcindor T.

Primitive neuroectodermal tumor (pnet) as somatic-type malignancy arising from an extragonadal germ cell tumor: clinical, pathological and molecular features of a case. Tumori, In Press
*Abu-Sanad, A, Warsi A, Michel RP, Nahal A, Popradi G, Storring JM, Liberman AS, Alcindor T.
Long-term remission after autologous stem-cell transplantation for relapsed histiocytic sarcoma. Current Oncology, In Press.

 

Ferri LE, Ades S, Alcindor T, Chasen M, Hickeson M, Artho G, Marcus V, Thirlwell MP Alcindor T, Nahal A.
Peri-Operative Docetaxel, Cisplatin, and 5-Flourouracil (DCF) for Locally Advanced Esophageal and Gastric Adenocarcinoma: Safety and Response Results from a Multi-Center Phase II Trial. Annals of Oncology, 2012 Jun;23(6):1512-7. Epub 2011 Oct 29.

 

Hanna WC, Roberge D, David M, Waschke KA, Sudarshan M, Mayrand S, Alcindor T, Ferri LE.
What is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer? Current Oncology, In press.

 

Mackay H, Au H, McWhirter E, Alcindor T, Jarvi A, MacAlpine K, Wang L, Wright JJ, Oza AM.
A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium. Investigational New Drugs, 2011 Mar 12. [Epub ahead of print]

Alcindor T, Beauger N.
Oxaliplatin: A review in the era of molecularly targeted therapy Current Oncology, 2011 Jan18(1):18-25.